Interestingly, the success of ACT using ex vivo-expanded autologous TILs is dependent on the presence of stem-like CD8+ T cells within transferred cells, demonstrating the crucial role of these particular CD8+ T cells in cell-based immunotherapies in human cancer [334]. The gene discussed is CD8A; the disease is cancer.